TASCON GESELLSCHAFT FUR OBERFLACHEN- UND MATERIALCHARAKTERISIERUNG MBH

Their core work

TASCON is a German analytical services SME in Münster whose core business — embedded in their name — is surface and material characterization. They apply techniques such as XPS (X-ray Photoelectron Spectroscopy) and ToF-SIMS to measure the chemical composition, structure, and properties of material surfaces at nanoscale resolution. In H2020, they contributed as a specialized third-party laboratory to two nanomedicine consortia: first providing characterization services to the European Nanomedicine Characterization Laboratory (EUNCL), and then supporting the development of regulatory science frameworks for nano-based medical products in the REFINE project. Their value to research consortia is as an expert measurements provider — bringing accredited analytical instrumentation and interpretation expertise that most academic or industrial partners cannot replicate in-house.

What they specialise in

How they've shifted over time

In their first H2020 project (EUNCL, 2015–2019), TASCON operated in a pure infrastructure role — providing characterization measurements to an EU-wide laboratory network with no recorded keyword signal beyond the project domain. By REFINE (2017–2022), their contribution had broadened into regulatory science: the project's keywords — regulatory framework, risk assessment, knowledge base, decision-support systems — indicate that characterization data was being fed directly into policy and compliance workflows for nano-based medical products. The trajectory is from measurement provider to regulatory-evidence contributor: the same analytical techniques, but increasingly embedded in the governance and risk assessment pipeline rather than purely scientific research.

TASCON is positioning its characterization expertise upstream of product approval — moving toward providing the analytical evidence base that regulators and medical device manufacturers need to demonstrate nano-safety compliance.

How they like to work

TASCON has participated exclusively as a third party in both recorded H2020 projects, meaning they were contracted by consortium members to deliver specific analytical services rather than shaping project direction. This is consistent with a specialist laboratory business model: they do not lead consortia and likely do not seek to, but they are brought in precisely because their instrumentation and expertise are not duplicated elsewhere in a consortium. Working with them likely means a clearly scoped service agreement — defined measurements, defined deliverables — rather than open-ended co-research.

Despite only two projects, TASCON has accumulated 19 unique consortium partners across 11 countries, reflecting how large the EUNCL and REFINE consortia were. Their network skews toward European nanomedicine and regulatory science communities rather than any single geography.

What sets them apart

TASCON occupies a narrow but strategically valuable niche: a commercial analytical laboratory that has been vetted and used inside peer-reviewed EU research consortia, which is rare for a private SME. For a project coordinator building a nanomedicine or medical device consortium, this means access to accredited characterization services with a documented track record in EU regulatory and research contexts — not just a commercial lab quoting from a brochure. Their combination of surface science instrumentation and growing familiarity with regulatory evidence requirements (risk assessment, decision-support, medicinal innovation) makes them particularly relevant for consortia targeting CE marking or EMA pathways for nano-based products.

Highlights from their portfolio

• EUNCL
  As part of the European Nanomedicine Characterization Laboratory (2015–2019), TASCON was embedded in an EU-wide infrastructure initiative to standardize the characterization of nanomedicines — a high-visibility role that validates their analytical capabilities at a continental scale.
• REFINE
  This 2017–2022 RIA project tackled the regulatory science gap for nano-based medical products, and TASCON's inclusion as a third party signals that their characterization data was considered robust enough to underpin regulatory decision-support tools and risk assessment frameworks.